M&As this week: Trivitron Healthcare, Corin Orthopaedics Holdings, Nichi-Iko Pharmaceutical

14 July 2016 (Last Updated July 14th, 2016 18:30)

Trivitron Healthcare, a medical technology company specialising in in-vitro diagnostic (IVD) devices, has acquired a 60% stake in Turkish firm Bome Sanayi Urunleri Dis. Tic. Ltd Sti., for a purchase consideration of €5m ($5.52m).

M&As this week

Trivitron Healthcare, a medical technology company specialising in in-vitro diagnostic (IVD) devices, has acquired a 60% stake in Turkish firm Bome Sanayi Urunleri Dis. Tic. Ltd Sti., for a purchase consideration of €5m ($5.52m). The remaining stake in the company will be held by the promoters.

The acquisition allows Trivitron to get direct access to the Turkish, Middle Eastern, African, South and South East Asian markets, through which it can expand its growth.

Corin Orthopaedics Holdings intends to acquire Wright Medical Group’s large joints (hip / knee) business for a purchase consideration of approximately $33m.

Corin has made a binding offer, according to which it will acquire all of the legacy tornier large joints business, which, following the transaction, will continue to be headquartered in Montbonnot, France.

"Corin has made a binding offer, according to which it will acquire all of the legacy tornier large joints business, which, following the transaction, will continue to be headquartered in Montbonnot, France."

The transaction, which is expected to close between Q3 and Q4 of 2016, will help Wright Medical to focus on extremities and biologics markets and to expand its growth profile.

Nichi-Iko Pharmaceutical, through its wholly-owned subsidiary Shepard Vision (Merger Sub), will acquire Sagent Pharmaceuticals for a cash consideration of $736m. The acquisition will be financed through bank loans and available cash.

The acquisition, which will close in Q2 of Nichi-Iko’s fiscal year ending March 2017, will enable the company to commercialise its biosimilar product pipeline, to further expand its platform in the US market, and to enhance its presence in injectables.

Ossen Innovation intends to acquire 90.27% stake in San MediTech (Huzhou) from America-Asia Diabetes Research Foundation.

Ossen has signed a non-binding letter of intent (LOI), according to which it will acquire all issued and outstanding equity interests of the Research Foundation in San MediTech and in exchange will issue 81,243,000 of its ordinary shares.


Image: A handshake. Photo: courtesy of Flazingo Photos.